Generic drug giant Mylan issued a statement this afternoon saying it was not interested in merging with Teva Pharmaceutical Industries, calling such a combination “without sound industrial logic or cultural fit.”

Mylan was responding to widespread speculation that Teva, based in Israel and the world’s biggest generic drug maker, was mulling an offer for Mylan.

“Mylan is fully committed to its stand-alone strategy, including its proposal to acquire Perrigo,” the company said.

Mylan, which earlier this year moved its headquarters to the Netherlands but maintains its base of operations in Cecil, last week revealed it had made an unsolicited, roughly $30 billion bid for the store-brand medication specialist Perrigo.

Advertise with us

Perrigo has said its board would consider Mylan’s offer, but has not yet publicly responded to the bid.

In its statement today, Mylan noted that if it were to receive a takeover offer, its board would "carefully consider it in exercising its fiduciary duties."

Patricia Sabatini: PSabatini@post-gazette.com; 412-263-3066.